Capital International Sarl Buys 24,055 Shares of Illumina, Inc. $ILMN

Capital International Sarl boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 24.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 120,752 shares of the life sciences company’s stock after purchasing an additional 24,055 shares during the quarter. Capital International Sarl owned about 0.08% of Illumina worth $11,468,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Loomis Sayles & Co. L P lifted its position in shares of Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock valued at $403,158,000 after acquiring an additional 78,317 shares during the period. AQR Capital Management LLC raised its position in shares of Illumina by 55.3% during the second quarter. AQR Capital Management LLC now owns 3,295,880 shares of the life sciences company’s stock worth $313,290,000 after acquiring an additional 1,174,295 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Illumina by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 2,869,187 shares of the life sciences company’s stock worth $272,921,000 after purchasing an additional 21,342 shares during the period. Bank of America Corp DE boosted its position in Illumina by 1.9% during the second quarter. Bank of America Corp DE now owns 1,930,843 shares of the life sciences company’s stock valued at $184,222,000 after acquiring an additional 35,167 shares during the last quarter. Finally, ARK Investment Management LLC boosted its position in shares of Illumina by 25.7% during the 3rd quarter. ARK Investment Management LLC now owns 1,467,879 shares of the life sciences company’s stock valued at $139,405,000 after purchasing an additional 299,801 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ILMN shares. Guggenheim boosted their price objective on Illumina from $144.00 to $170.00 and gave the company a “buy” rating in a report on Monday, January 26th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Illumina in a research report on Monday, December 29th. Barclays raised their price target on shares of Illumina from $100.00 to $110.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. UBS Group reissued a “neutral” rating and set a $135.00 price objective on shares of Illumina in a report on Friday, February 6th. Finally, Stifel Nicolaus boosted their target price on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. Six investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $129.69.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $124.28 on Tuesday. Illumina, Inc. has a twelve month low of $68.70 and a twelve month high of $155.53. The firm has a market capitalization of $19.00 billion, a P/E ratio of 22.80, a P/E/G ratio of 2.38 and a beta of 1.45. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55. The stock’s 50-day simple moving average is $134.17 and its two-hundred day simple moving average is $119.55.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 5th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a return on equity of 31.04% and a net margin of 19.57%.The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the business earned $0.95 EPS. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Insider Activity at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Scott M. Davies sold 323 shares of Illumina stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the completion of the transaction, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. This represents a 1.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.17% of the stock is currently owned by insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.